Patents by Inventor Carl BJARTMAR

Carl BJARTMAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
    Publication number: 20230070534
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Application
    Filed: August 23, 2022
    Publication date: March 9, 2023
    Inventors: Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
  • Bis-choline tetrathiomolybdate for treating Wilson disease
    Patent number: 11510944
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 29, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
  • Bis-choline tetrathiomolybdate for treating Wilson Disease
    Patent number: 11419832
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 23, 2022
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
  • Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
    Publication number: 20210177894
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 17, 2021
    Inventors: Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
  • Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
    Publication number: 20210137972
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Application
    Filed: December 4, 2018
    Publication date: May 13, 2021
    Inventors: Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
  • Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
    Publication number: 20210093588
    Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
    Type: Application
    Filed: August 19, 2020
    Publication date: April 1, 2021
    Inventors: Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA